On June 30, 2020, Quantel Medical by Lumibird finalized its acquisition of Ellex. The coming together of these two companies—both renowned in the field of ophthalmology—represents a real milestone in their history. Quantel Medical and Ellex have a shared heritage in the development of cutting-edge technologies for the diagnosis and treatment of the leading causes of blindness worldwide: glaucoma, cataracts, AMD and diabetic retinopathy.

At Glaukos, our focus is to develop and lead the global ophthalmic market with novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases—therapies that advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide.

Heidelberg Engineering continuously optimizes imaging and healthcare IT technologies to provide ophthalmic diagnostic solutions that empower clinicians to improve patient care. The company has collaborated with scientists, clinicians and industry to develop innovative products that deliver clinically relevant benefits.

Uncompromising quality and education play a large part in fostering the diagnostic confidence that has become synonymous with the global brand. Heidelberg Engineering’s growing product portfolio combines these core technologies: confocal microscopy, scanning lasers and optics, optical coherence tomography (OCT), real-time image processing and analytics, multimodal image management solutions, electronic medical records (EMR) and data mining.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.

Optos, invented ultra-widefield optomap retinal imaging – the ONLY true UWF imaging technology which documents 82% of the retina in a single capture. Over 1,000 peer-reviewed studies confirm that optomap enables doctors to more effectively detect and manage retinal pathology. optomap is revolutionizing eye care and helping doctors save sight and save lives.

Transforming Ophthalmology and Optometry by addressing the underlying causes of the world’s most prevalent eye diseases.

Revolutionizing eye care in Nebraska and beyond. With the Truhlsen Eye Institute’s cutting-edge research, education, and patient care, UNMC joined the ranks of national centers of excellence in ophthalmology. Combining state-of-the art diagnostic medicine with the latest advances in clinical research, the Institute brings hope to patients suffering from blinding diseases such as macular degeneration, glaucoma, corneal dystrophies, uveitis, and other ocular inflammatory diseases. Through UNMC’s partnership with Nebraska Medicine, the Institute serves as a preeminent provider of all eye care services for this region. The Truhlsen Eye Institute’s main location features outpatient eye exam facilities, an optical shop, and a comprehensive regional diagnostic center.

ZEISS offers complete solutions to diagnose, manage, and treat ophthalmic disease. The comprehensive ZEISS portfolio is designed to meet the demands of eye care professionals in glaucoma, retina, comprehensive, cataract and refractive specialties. With additional solutions in data management, ZEISS products help doctors to deliver the best possible patient care.